Time to complete remission is an independent determinant of survival after intensive chemotherapy in AML.

IF 23.1 1区医学 Q1 HEMATOLOGY

Blood Pub Date : 2025-07-29 DOI:10.1182/blood.2025028594

Rithin Nedumannil,Michael Ashby,James P Rowland,Jacques A J Malherbe,Jared Fairbank,Kelli Gray,Sun Loo,Matthew Wright,John Reynolds,Devendra K Hiwase,Paula Marlton,Shaun A Fleming,Ashish Bajel,Andrew H Wei

引用次数: 0

Abstract

The purpose of this study was to explore and determine the optimal landmark for defining complete remission after intensive induction therapy that best correlates with long-term survival outcome among patients with newly diagnosed acute myeloid leukemia (AML).

查看原文本刊更多论文

完全缓解时间是AML强化化疗后生存的独立决定因素。

本研究的目的是探索和确定新诊断的急性髓性白血病（AML）患者在强化诱导治疗后完全缓解的最佳标志，该标志与长期生存结果最相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood 医学-血液学

CiteScore

23.60

自引率

3.90%

发文量

955

审稿时长

1 months

期刊介绍： Blood, the official journal of the American Society of Hematology, published online and in print, provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology. Primary research articles will be published under the following scientific categories: Clinical Trials and Observations; Gene Therapy; Hematopoiesis and Stem Cells; Immunobiology and Immunotherapy scope; Myeloid Neoplasia; Lymphoid Neoplasia; Phagocytes, Granulocytes and Myelopoiesis; Platelets and Thrombopoiesis; Red Cells, Iron and Erythropoiesis; Thrombosis and Hemostasis; Transfusion Medicine; Transplantation; and Vascular Biology. Papers can be listed under more than one category as appropriate.